Three products, including two devices, will receive Medicare hospital inpatient new-technology add-on payments for the first time in fiscal year 2014. Two additional devices that had sought the payments will not qualify because they have yet to gain FDA approval. The Centers for Medicare and Medicaid Services (CMS) announced the decisions in its final inpatient prospective payment system rule, issued August 2 and set to take effect October 1.
The successful applicants were Second Sight Medical Products Inc.’s Argus II retinal prosthesis system, Cook Medical Inc.’s Zilver PTX paclitaxel-eluting peripheral artery stent and CSL Behring’s drug,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?